Noubar Afeyan - Jan 4, 2023 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
Noubar B. Afeyan, Ph.D. By: /s/ Noubar B. Afeyan, Ph.D.
Stock symbol
MRNA
Transactions as of
Jan 4, 2023
Transactions value $
-$1,821,500
Form type
4
Date filed
1/6/2023, 06:30 PM
Previous filing
Dec 23, 2022
Next filing
Jan 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Sale -$1.82M -10K -0.44% $182.15 2.27M Jan 4, 2023 Direct F1
holding MRNA Common Stock 12.9M Jan 4, 2023 By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. F2
holding MRNA Common Stock 3.92K Jan 4, 2023 By Flagship Pioneering, Inc. F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021, as amended on March 11, 2022.
F2 10,801,059 shares are held directly by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and 2,081,760 shares are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F3 3,924 shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.